NASDAQ : ATTO
Attovia Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 15.19 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 693.44M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 687.05M |
| Enterprise Value | 576.25M |
Dates
| Measure | Value |
|---|
| Earnings Date | Sep 2, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 45.65M |
| Shares Outstanding | 45.65M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +2.03% |
| Owned by Insiders (%) | 1.58% |
| Owned by Institutions (%) | 9.74% |
| Float | 26.26M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 381.70 |
| Forward PS | n/a |
| PB Ratio | 6.09 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 320.14 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 9.39 |
| Quick Ratio | 9.20 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -65.84% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | $40,909 |
| Profits Per Employee | -$1.59M |
| Employee Count | 44 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 18.55 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 42.35 |
| Average Volume (20 Days) | 370,249 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 1.45M |
| Short Previous Month | 1.65M |
| Short % of Shares Out | 3.18% |
| Short % of Float | 5.53% |
| Short Ratio (days to cover) | 3.01 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 1.80M |
| Gross Profit | -62.46M |
| Operating Income | -76.19M |
| Pretax Income | -70.38M |
| Net Income | -70.11M |
| EBITDA | -75.25M |
| EBIT | -76.19M |
| Loss Per Share | -$17.01 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 115.13M |
| Total Debt | 4.33M |
| Net Cash | 110.81M |
| Net Cash Per Share | $2.43 |
| Equity (Book Value) | 112.77M |
| Book Value Per Share | -32.12 |
| Working Capital | 105.79M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -67.43M |
| Capital Expenditures | -788,000 |
| Depreciation & Amortization | 942,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -68.22M |
| FCF Per Share | -$1.49 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | -4,232.94% |
| Pretax Margin | -3,910.00% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -113.02% |
| FCF Yield | -9.93% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $42.20 |
| Price Target Difference | 180.40% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -2.6 |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |